Susanna Naggie
Associate Professor of Medicine
Dr. Susanna Naggie completed her medical education at Johns Hopkins School of Medicine and her internal medicine training at Duke University Medical Center (DUMC), where she also served as a Chief Resident in Internal Medicine. She completed her Infectious Diseases (ID) fellowship training at Duke and then joined the faculty in the Division of ID. She is an Associate Professor of Medicine with Tenure and currently holds joint appointments at the Duke Clinical Research Institute (DCRI, Director of ID Research), and at the Durham Veterans Affairs Medical Center (DVAMC). Dr. Naggie has dedicated her academic career to the care of patients with HIV and viral hepatitis, with a research program focused on understanding the mechanisms of accelerated liver fibrogenesis in this population and the extrahepatic health outcomes attributed to HCV in persons with HIV infection. In addition to her investigator-initiated research program, Dr. Naggie is also involved in multiple clinical trials and clinical registries with a particular focus on HIV and liver disease. She is the prior co-Chair of the AASLD/IDSA HCV Guidance Committee and is currently Chair of the AIDS Clinical Trials Group Viral Hepatitis Transformative Science Group Committee and a member of the DHHS Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV and the CDC/NIH/IDSA-HIVMA Opportunistic Infections Guideline Committee. For the past two years Dr. Naggie has served as the Medical Director of the Duke Department of Medicine Clinical Research Unit.
Current Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Infectious Diseases, Medicine 2017
- Vice Dean for Clinical Research, Duke Clinical Research Institute, Institutes and Centers 2020
- Member in the Duke Clinical Research Institute, Duke Clinical Research Institute, Institutes and Centers 2009
Contact Information
- 200 Morris Street, 6th Floor - 6410, Durham, NC 27701
- Duke Box 3850, Durham, NC 27710
-
susanna.naggie@duke.edu
(919) 684-2584
- Background
-
Education, Training, & Certifications
- Fellow in Infectious Diseases, Medicine, Duke University 2007 - 2009
- Chief Medical Resident - VAMC, Medicine, Duke University 2006 - 2007
- Medical Resident, Medicine, Duke University 2002 - 2005
- M.D., Johns Hopkins University 2002
-
Medical Licensure
- 2005-00684. North Carolina. 2019
-
Duke Appointment History
- Associate Professor of Medicine, Medicine, Infectious Diseases, Medicine 2015 - 2017
- Assistant Professor of Medicine, Medicine, Infectious Diseases, Medicine 2009 - 2015
- Medical Instructor in the Department of Medicine, Medicine, General Internal Medicine, Medicine 2005 - 2007
-
Leadership & Clinical Positions at Duke
-
Durham VA Medical Center Staff Physician 2011-present
Duke Clinical Research Institute Director, Infectious Diseases 2012-present
Duke University School of Medicine Associate Professor of Medicine 2015-2017
Durham VA Medical Center Medical Director, Infectious Diseases 2016-present
Duke University Medical Center Medical Director, Medicine CRU 2016-2019
Duke University School of Medicine Associate Professor with Tenure 2017-present
Duke University School of Medicine Associate Dean, Clinical Research 2019-present
-
- Recognition
-
In the News
-
DEC 21, 2020 -
OCT 30, 2020 School of Medicine Magnify -
APR 2, 2020 -
JUN 19, 2015
-
- Research
-
Selected Grants
- Interdisciplinary Research Training Program in AIDS awarded by National Institutes of Health 2010 - 2025
- VTEU 14-0053 Task C Option 2 Protocol Implementation awarded by National Institutes of Health 2018 - 2024
- Unified Program for Therapeutics in Children awarded by National Institutes of Health 2019 - 2024
- VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053 awarded by National Institutes of Health 2015 - 2024
- VTEU 14-0053 Task C Option 4 Protocol Implementation awarded by National Institutes of Health 2019 - 2023
- HERO Program, HERO Registry, HERO-HCQ Trial awarded by Patient Centered Outcomes Research Institute 2020 - 2023
- A Multidisciplinary Approach to Primary Cardiovascular Disease Prevention in HIV-infected (K23) awarded by National Institutes of Health 2018 - 2022
- Rapid diagnosis and quantification of HIV by direct capture, labelling and detection of individual virions awarded by National Institutes of Health 2019 - 2022
- Duke Resident Physician-Scientist Program - NIAID awarded by National Institutes of Health 2018 - 2022
- VTEU 14-0053 Task C Option 3 Protocol Implementation awarded by National Institutes of Health 2015 - 2022
- Identification of Novel Bioactive Lipid Metabolites for Predicting Liver-related Outcomes in Persons Co-Infected with HIV and HCV awarded by National Institutes of Health 2017 - 2022
- Molecular Mycology and Pathogenesis Training Program awarded by National Institutes of Health 2019 - 2021
- NIAID Virology Quality Assurance - Option 1 awarded by National Institutes of Health 2019 - 2021
- Randomized Trial to Prevent Vascular Events in HIV- REPRIEVE (A5332) awarded by Massachusetts General Hospital 2015 - 2021
- Ancillary Studies of NAFLD and NASH in HIV infected Adults awarded by Indiana University 2020 - 2021
- Janssen HERO Vaccine Trial Start Up Budget awarded by Janssen Pharmaceutica, Inc. 2020
- Leadership and Operations Center (LOC) AIDS Clinical Trials Group (ACTG) Protocol Chair Support for A5380 awarded by University of California - Los Angeles 2018 - 2020
- Leadership and Operations Center (LOC), Aids Clinical Trial Group (ACTG) HEP Committee Chair awarded by University of California - Los Angeles 2018 - 2020
- HCV/HIV Co-infection Registry awarded by Gilead Sciences, Inc. 2015 - 2020
- First-in-human (FIH) Safety and Dose Ranging Study of TT-034 in Patients with Chronic Hepatitis C (CHC) Infection awarded by Tacere Therapeutics 2014 - 2019
- VTEU 14-0053 Task Area A Project Logistics and Site Activation awarded by National Institutes of Health 2018 - 2019
- M16-135 awarded by AbbVie Inc. 2017 - 2019
- VTEU: Task Area C: Protocol Implementation - Option 2 Protocol #14-0053 awarded by National Institutes of Health 2015 - 2019
- RCT of an Integrated Treatment of Persons with Co-Occurring HCV and Alcohol Abuse awarded by National Institutes of Health 2013 - 2019
- The Follow Up Study Regarding the Safety and Efficacy of TT-034, a Genetically-Modified Adeno-Associated Virus Designed to Target Hepatitis C in a Study Under Protocol B2801001. awarded by Tacere Therapeutics 2014 - 2019
- ACTG, Aids Clinical Trials Group Hepatitis TSG Vice-Chair awarded by Brigham and Women's Hospital 2015 - 2018
- mHealth Peer Support to Reduce Rates of STIs in Black MSM PrEP Users awarded by National Institutes of Health 2018
- Systems Biology Approaches for Predicting Cardiometabolic Risk in Persons Living with HIV awarded by National Institutes of Health 2015 - 2018
- GS-US-366-1992 awarded by Gilead Sciences, Inc. 2016 - 2018
- ACTG A5327 Protocol Chair Support (PCS) awarded by Brigham and Women's Hospital 2015 - 2017
- VTEU: Base -Task Area A: Project Logistics and Site Activation Protocol #14-0053 awarded by National Institutes of Health 2015 - 2017
- A phase3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination for 12 weeks in Subjcts with Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection awarded by Gilead Sciences, Inc. 2015 - 2017
- Gilead GS-342-1553 A randomized, open-label study to evaluate the efficacy and safety of Sofosbuvir/GS-5816 Fixed Dose Combination - Ribavirin for 24 weeks in Chronic HCV infected subjects who participated in a prior Gilead-sponsored HCV study. awarded by Gilead Sciences, Inc. 2014 - 2017
- GS_US_342-1140 awarded by Gilead Sciences, Inc. 2014 - 2017
- VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053 awarded by National Institutes of Health 2015 - 2016
- The Pharmacokinetics of Extended Duration High-dose Cefixime Co-administered with Azithromycin for the Decreased Susceptibility of Neisseria gonorrhoeae: A Phase I Pilot Study awarded by National Institutes of Health 2015 - 2016
- Phase 3 multicenter, open-label study to investigate the efficacy and safety of Sofosbuvir/Ledipasvir fixed-dose combination for 12 weeks in subjects with chronic genotype 1 or 4 HCV and HIV-1 co-infection awarded by Gilead Sciences, Inc. 2014 - 2016
- ACTG, Aids Clinical Trials Group awarded by Brigham and Women's Hospital 2015
- Moving Towards More Individualized Therapies in HIV/HCV Co-infected Patients awarded by National Institutes of Health 2011 - 2015
- Collaboration between Duke University and the NIAID awarded by National Institutes of Health 2010 - 2012
-
External Relationships
- AbbVie Pharmaceuticals
- BioMarin Pharmaceutical, Inc.
- Bristol-Myers Squibb
- Gilead Sciences, Inc.
- IAS-USA
- Theratechnologies
- Vir Biotechnology
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Naggie, Susanna, and Anna S. Lok. “New Therapeutics for Hepatitis B: The Road to Cure.” Annu Rev Med 72 (January 27, 2021): 93–105. https://doi.org/10.1146/annurev-med-080119-103356.Full Text Link to Item
-
Lee, Tzu-Hao, Austin Chan, William Bryan, Lawrence Park, Mohamed Hashem, Mary Townsend, Cynthia Moylan, Rachel Britt, Steve Choi, and Susanna Naggie. “Proton pump inhibitor usage reduces sustained viral response rates for veterans with HIV/HCV coinfection on ledipasvir/sofosbuvir: a real-world study from a multicentre VA cohort.” J Viral Hepat, December 30, 2020. https://doi.org/10.1111/jvh.13462.Full Text Link to Item
-
Naggie, Susanna, and David Wyles. “Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection: Fulfilling the Potential on the Road to Elimination.” J Infect Dis 222, no. Supplement_9 (November 27, 2020): S741–44. https://doi.org/10.1093/infdis/jiaa425.Full Text Link to Item
-
Naggie, Susanna, Sam Lusk, J Will Thompson, Meredith Mock, Cynthia Moylan, Joseph E. Lucas, Laura Dubois, Lisa St John-Williams, M Arthur Moseley, and Keyur Patel. “Metabolomic Signature as a Predictor of Liver Disease Events in Patients With HIV/HCV Coinfection.” J Infect Dis 222, no. 12 (November 13, 2020): 2012–20. https://doi.org/10.1093/infdis/jiaa316.Full Text Link to Item
-
McKnight, Ashley H., Mary L. Townsend, Mohamed G. Hashem, Susanna Naggie, Lawrence P. Park, and Rachel B. Britt. “Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.” Ann Pharmacother 54, no. 11 (November 2020): 1057–64. https://doi.org/10.1177/1060028020921166.Full Text Link to Item
-
Okeke, Nwora Lance, Katherine R. Schafer, Eric G. Meissner, Jan Ostermann, Ansal D. Shah, Brian Ostasiewski, Evan Phelps, et al. “Cardiovascular Disease Risk Management in Persons With HIV: Does Clinician Specialty Matter?” Open Forum Infect Dis 7, no. 9 (September 2020): ofaa361. https://doi.org/10.1093/ofid/ofaa361.Full Text Link to Item
-
Moorman, Anne C., Marie A. de Perio, Ronald Goldschmidt, Carolyn Chu, David Kuhar, David K. Henderson, Susanna Naggie, et al. “Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020.” Mmwr Recomm Rep 69, no. 6 (July 24, 2020): 1–8. https://doi.org/10.15585/mmwr.rr6906a1.Full Text Link to Item
-
Fuchs, Michael, Alexander Monto, Norbert Bräu, Mariem Charafeddine, Warren Schmidt, Michael Kozal, Susanna Naggie, et al. “Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.” J Med Virol, December 12, 2019. https://doi.org/10.1002/jmv.25655.Full Text Link to Item
-
Morrison, Margaret, Heather Y. Hughes, Susanna Naggie, and Wing-Kin Syn. “Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?” Dig Dis Sci 64, no. 12 (December 2019): 3394–3401. https://doi.org/10.1007/s10620-019-05861-7.Full Text Link to Item
-
Ocal, Selin, Andrew J. Muir, and Susanna Naggie. “Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy.” N C Med J 80, no. 6 (November 2019): 352–55. https://doi.org/10.18043/ncm.80.6.352.Full Text Link to Item
-
Alenezi, Fawaz, Gerald S. Bloomfield, Nwora Lance Okeke, Poonam Velagapudi, Loai Abudaqa, Nkechinyere Ijioma, Allison Dunning, et al. “Global Longitudinal Strain and Immune Status in Patients Living With Human Immunodeficiency Virus.” Am J Cardiol 124, no. 6 (September 15, 2019): 966–71. https://doi.org/10.1016/j.amjcard.2019.06.013.Full Text Link to Item
-
Naggie, Susanna, Daniel S. Fierer, Michael D. Hughes, Arthur Y. Kim, Annie Luetkemeyer, Vincent Vu, Jhoanna Roa, et al. “Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.” Clin Infect Dis 69, no. 3 (July 18, 2019): 514–22. https://doi.org/10.1093/cid/ciy913.Full Text Link to Item
-
Marks, Kristen, and Susanna Naggie. “Management of Hepatitis C in 2019.” Jama, May 17, 2019. https://doi.org/10.1001/jama.2019.5353.Full Text Link to Item
-
Naggie, Susanna, Meredith Clement, Sam Lusk, Anu Osinusi, Tiffany Himmel, Joseph E. Lucas, Will J. Thompson, et al. “Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations.” Proteomics. Clinical Applications 13, no. 3 (May 2019): e1800006. https://doi.org/10.1002/prca.201800006.Full Text
-
Naggie, Susanna, and Christian B. Ramers. “Sustained Virologic Response in People Who Inject Drugs and/or Who Are on Opioid Agonist Therapy: Is 90% Enough?” Hepatol Commun 3, no. 4 (April 2019): 453–55. https://doi.org/10.1002/hep4.1347.Full Text Link to Item
-
Chan, Austin, Lawrence Park, Lauren F. Collins, Curtis Cooper, Michael Saag, Douglas Dieterich, Mark Sulkowski, and Susanna Naggie. “Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort.” Open Forum Infect Dis 6, no. 1 (January 2019): ofy273. https://doi.org/10.1093/ofid/ofy273.Full Text Link to Item
-
Naggie, Susanna. “Treating HCV Infection: It Doesn't Get Much Better Than This.” Top Antivir Med 26, no. 4 (January 2019): 104–8.Link to Item
-
AASLD-IDSA HCV Guidance Panel, Alina. “Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.” Clin Infect Dis 67, no. 10 (October 30, 2018): 1477–92. https://doi.org/10.1093/cid/ciy585.Full Text Link to Item
-
Proeschold-Bell, Rae Jean, Donna M. Evon, Christina Makarushka, John B. Wong, Santanu K. Datta, Jia Yao, Ashwin A. Patkar, et al. “The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial.” Contemporary Clinical Trials 72 (September 2018): 73–85. https://doi.org/10.1016/j.cct.2018.07.003.Full Text
-
MacBrayne, Christine E., Kristen M. Marks, Daniel S. Fierer, Susanna Naggie, Raymond T. Chung, Michael D. Hughes, Arthur Y. Kim, et al. “Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.” J Antimicrob Chemother 73, no. 8 (August 1, 2018): 2112–19. https://doi.org/10.1093/jac/dky146.Full Text Link to Item
-
Okeke, Nwora Lance, Fawaz Alenezi, Gerald S. Bloomfield, Allison Dunning, Meredith E. Clement, Svati H. Shah, Susanna Naggie, and Eric J. Velazquez. “Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort.” J Card Fail 24, no. 8 (August 2018): 496–503. https://doi.org/10.1016/j.cardfail.2018.06.003.Full Text Link to Item
-
Naggie, Susanna, Marzena Swiderska-Syn, Steve Choi, Sam Lusk, Audrey Lan, Guido Ferrari, Wing-Kin Syn, Cynthia D. Guy, and Anna Mae Diehl. “Markers of Tissue Repair and Cellular Aging Are Increased in the Liver Tissue of Patients With HIV Infection Regardless of Presence of HCV Coinfection.” Open Forum Infect Dis 5, no. 7 (July 2018): ofy138. https://doi.org/10.1093/ofid/ofy138.Full Text Link to Item
-
Clement, Meredith E., Lauren F. Collins, Julius M. Wilder, Michael Mugavero, Taryn Barker, and Susanna Naggie. “Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.” Infect Dis Clin North Am 32, no. 2 (June 2018): 407–23. https://doi.org/10.1016/j.idc.2018.02.005.Full Text Link to Item
-
Kleinstein, Sarah E., Patrick R. Shea, Luisa M. Stamm, Mark Sulkowski, David B. Goldstein, and Susanna Naggie. “Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV-Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 66, no. 12 (June 2018): 1953–56. https://doi.org/10.1093/cid/cix1051.Full Text
-
Carlton-Smith, C., J. A. Holmes, S. Naggie, A. Lidofsky, G. M. Lauer, A. Y. Kim, R. T. Chung, and R. T. of the ACTG A5327 study group. “IFN-free therapy is associated with restoration of type I IFN response in HIV-1 patients with acute HCV infection who achieve SVR.” J Viral Hepat 25, no. 5 (May 2018): 465–72. https://doi.org/10.1111/jvh.12836.Full Text Link to Item
-
Okeke, Nwora Lance, Damian M. Craig, Michael J. Muehlbauer, Olga Ilkayeva, Meredith E. Clement, Susanna Naggie, and Svati H. Shah. “Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study.” Metabolomics 14, no. 3 (March 2018). https://doi.org/10.1007/s11306-018-1318-z.Full Text Link to Item
-
Clement, Meredith E., Li Lin, Ann Marie Navar, Nwora Lance Okeke, Susanna Naggie, and Pamela S. Douglas. “Lower likelihood of cardiac procedures after acute coronary syndrome in patients with human immunodeficiency virus/acquired immunodeficiency syndrome.” Medicine (Baltimore) 97, no. 6 (February 2018): e9849. https://doi.org/10.1097/MD.0000000000009849.Full Text Link to Item
-
Collins, Lauren F., Austin Chan, Jiayin Zheng, Shein-Chung Chow, Julius M. Wilder, Andrew J. Muir, and Susanna Naggie. “Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.” Open Forum Infect Dis 5, no. 1 (January 2018): ofx264. https://doi.org/10.1093/ofid/ofx264.Full Text Open Access Copy Link to Item
-
Morgan, Jake R., Arthur Y. Kim, Susanna Naggie, and Benjamin P. Linas. “The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.” Open Forum Infect Dis 5, no. 1 (January 2018): ofx267. https://doi.org/10.1093/ofid/ofx267.Full Text Link to Item
-
Lok, Anna S., Raymond T. Chung, Hugo E. Vargas, Arthur Y. Kim, Susanna Naggie, and William G. Powderly. “Benefits of Direct-Acting Antivirals for Hepatitis C.” Ann Intern Med 167, no. 11 (December 5, 2017): 812–13. https://doi.org/10.7326/M17-1876.Full Text Link to Item
-
Zuckerman, Autumn, Cody A. Chastain, and Susanna Naggie. “Retreatment Options Following HCV Direct Acting Antiviral Failure.” Curr Treat Options Infect Dis 9, no. 4 (December 2017): 389–402. https://doi.org/10.1007/s40506-017-0136-6.Full Text Link to Item
-
Babich, Tanya, Oren Zusman, Michal Elbaz, Haim Ben-Zvi, Mical Paul, Leonard Leibovici, and Tomer Avni. “Empirical Antibiotic Treatment Does Not Improve Outcomes in Catheter-Associated Urinary Tract Infection: Prospective Cohort Study.” Clinical Infectious Diseases 65, no. 11 (November 13, 2017): 1799–1805. https://doi.org/10.1093/cid/cix680.Full Text
-
Powderly, William G., Susanna Naggie, Arthur Y. Kim, Hugo E. Vargas, Raymond T. Chung, and Anna S. Lok. “IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C.” Clin Infect Dis 65, no. 11 (November 13, 2017): 1773–75. https://doi.org/10.1093/cid/cix620.Full Text Link to Item
-
Lok, Anna S., Raymond T. Chung, Hugo E. Vargas, Arthur Y. Kim, Susanna Naggie, and William G. Powderly. “Comments on cochrane review on direct-acting antivirals for hepatitis C.” Hepatology 66, no. 4 (October 2017): 1016–19. https://doi.org/10.1002/hep.29366.Full Text Link to Item
-
Wyles, David, Norbert Bräu, Shyam Kottilil, Eric S. Daar, Peter Ruane, Kimberly Workowski, Anne Luetkemeyer, et al. “Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study.” Clin Infect Dis 65, no. 1 (July 1, 2017): 6–12. https://doi.org/10.1093/cid/cix260.Full Text Link to Item
-
Burton, Mary Jane, and Susanna Naggie. “Real-World Effectiveness of DAA Therapies in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection: 996 Veterans Can't Be Wrong.” Clin Infect Dis 64, no. 12 (June 15, 2017): 1721–23. https://doi.org/10.1093/cid/cix117.Full Text Link to Item
-
Chan, Austin, Keyur Patel, and Susanna Naggie. “Genotype 3 Infection: The Last Stand of Hepatitis C Virus.” Drugs 77, no. 2 (February 2017): 131–44. https://doi.org/10.1007/s40265-016-0685-x.Full Text Link to Item
-
Ho, Samuel B., Alexander Monto, Adam Peyton, David E. Kaplan, Sean Byrne, Scott Moon, Amanda Copans, et al. “Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities.” Clinical Gastroenterology and Hepatology : The Official Clinical Practice Journal of the American Gastroenterological Association 15, no. 2 (February 2017): 282–88. https://doi.org/10.1016/j.cgh.2016.05.024.Full Text
-
Naggie, Susanna, and Andrew J. Muir. “Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs.” Annu Rev Med 68 (January 14, 2017): 345–58. https://doi.org/10.1146/annurev-med-052915-015720.Full Text Link to Item
-
Alam, Imtiaz, Kimberley Brown, Cynthia Donovan, Jamie Forlenza, Kris Lauwers, Mitchell A. Mah’moud, Richard Manch, et al. “Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study.” Open Forum Infect Dis 4, no. 1 (2017): ofw258. https://doi.org/10.1093/ofid/ofw258.Full Text Link to Item
-
Naggie, Susanna, David P. Holland, Mark S. Sulkowski, and David L. Thomas. “Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing.” Clin Infect Dis 64, no. 1 (January 1, 2017): 92–99. https://doi.org/10.1093/cid/ciw656.Full Text Link to Item
-
Katrak, Shereen, Lawrence P. Park, Christopher Woods, Andrew Muir, Charles Hicks, and Susanna Naggie. “Patterns of Healthcare Utilization Among Veterans Infected With Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Coinfected With HIV/HCV: Unique Burdens of Disease.” Open Forum Infect Dis 3, no. 3 (September 2016): ofw173. https://doi.org/10.1093/ofid/ofw173.Full Text Link to Item
-
Wong, Tammy C., Audrey Lan, Jennifer J. Kiser, Peter L. Anderson, Keyur Patel, Hans Tillman, and Susanna Naggie. “Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.” Hepatology 64, no. 3 (September 2016): 999–1000. https://doi.org/10.1002/hep.28461.Full Text Link to Item
-
Clement, Meredith E., Lawrence P. Park, Ann Marie Navar, Nwora Lance Okeke, Michael J. Pencina, Pamela S. Douglas, and Susanna Naggie. “Statin Utilization and Recommendations Among HIV- and HCV-infected Veterans: A Cohort Study.” Clin Infect Dis 63, no. 3 (August 1, 2016): 407–13. https://doi.org/10.1093/cid/ciw289.Full Text Link to Item
-
Cooper, Curtis, Susanna Naggie, Michael Saag, Jenny C. Yang, Luisa M. Stamm, Hadas Dvory-Sobol, LingLing Han, et al. “Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 63, no. 4 (August 2016): 528–31. https://doi.org/10.1093/cid/ciw349.Full Text
-
Bhagani, S., C. Cooper, S. Naggie, M. Saag, J. Yang, L. Stamm, M. Natha, et al. “Retreatment of patients co-infected with HCV and HIV-1 who failed 12 weeks of ledipasvir/sofosbuvir.” Hiv Medicine 17 (April 1, 2016): 38–38.Link to Item
-
Suhy, David, Keyur Patel, Georgina Kilfoil, David L. Wyles, Susanna Naggie, Eric Lawitz, Stephen Bradley, and Per Lindell. “Phase I/IIa study of TT-034, a DNA-directed RNA interference agent (ddRNAi) delivered as a single administration for the treatment of subjects with chronic hepatitis C virus (HCV).” Hepatology 62, no. 6 (December 1, 2015): 1386A-1386A.Link to Item
-
Muir, Andrew J., and Susanna Naggie. “Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?” Clin Gastroenterol Hepatol 13, no. 12 (November 2015): 2166–72. https://doi.org/10.1016/j.cgh.2015.07.015.Full Text Link to Item
-
AASLD/IDSA HCV Guidance Panel, Julian F. R. “Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.” Hepatology 62, no. 3 (September 2015): 932–54. https://doi.org/10.1002/hep.27950.Full Text Link to Item
-
Rockstroh, J., C. Cooper, S. Naggie, M. Saag, J. Yang, L. Stamm, P. Pang, J. McHutchison, D. Dieterich, and M. Sulkowski. “A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection: the Phase 3 ION-4 study.” Journal of Viral Hepatitis 22 (September 1, 2015): 24–24.Link to Item
-
Naggie, Susanna, Curtis Cooper, Michael Saag, Kimberly Workowski, Peter Ruane, William J. Towner, Kristen Marks, et al. “Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.” N Engl J Med 373, no. 8 (August 20, 2015): 705–13. https://doi.org/10.1056/NEJMoa1501315.Full Text Link to Item
-
Younossi, Zobair M., Maria Stepanova, Mark Sulkowski, Susanna Naggie, Massimo Puoti, Chloe Orkin, and Sharon L. Hunt. “Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.” The Journal of Infectious Diseases 212, no. 3 (August 2015): 367–77. https://doi.org/10.1093/infdis/jiv005.Full Text
-
Naggie, Susanna, Curtis Cooper, Michael Saag, Jenny C. Yang, Luisa M. Stamm, Philip S. Pang, John G. McHutchison, Douglas Dieterich, and Mark S. Sulkowski. “Ledipasvir/sofosbuvir for 12 weeks in patients co-infected with HCV and HIV-1.” Journal of the International Aids Society 18 (July 1, 2015). https://doi.org/10.7448/IAS.18.5.20362.Full Text Link to Item
-
Horner, Stacy M., and Susanna Naggie. “Successes and Challenges on the Road to Cure Hepatitis C.” Plos Pathog 11, no. 6 (June 2015): e1004854. https://doi.org/10.1371/journal.ppat.1004854.Full Text Open Access Copy Link to Item
-
Matthews, G. V., J. Neuhaus, S. Bhagani, S. H. Mehta, E. Vlahakis, M. Doroana, S. Naggie, et al. “Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.” Hiv Med 16 Suppl 1 (April 2015): 129–36. https://doi.org/10.1111/hiv.12241.Full Text Link to Item
-
Naggie, Susanna, Keyur Patel, Lan-Yan Yang, Shein-Chung Chow, Victoria Johnson, John R. Guyton, Andrew J. Muir, Mark Sulkowski, and Charles Hicks. “Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals.” Open Forum Infect Dis 2, no. 2 (April 2015): ofv066. https://doi.org/10.1093/ofid/ofv066.Full Text Link to Item
-
Naggie, Susanna, and Arthur Y. Kim. “PHOTON-2: hope for patients with HIV and HCV co-infection?” Lancet 385, no. 9973 (March 21, 2015): 1052–54. https://doi.org/10.1016/S0140-6736(15)60122-2.Full Text Link to Item
-
Meissner, Eric G., Yu-Jin Lee, Anu Osinusi, Zayani Sims, Jing Qin, Dan Sturdevant, John McHutchison, et al. “Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients.” Hepatology 61, no. 3 (March 2015): 790–801. https://doi.org/10.1002/hep.27424.Full Text Link to Item
-
Norton, Brianna, and Susanna Naggie. “The clinical management of HCV in the HIV-infected patient.” Antivir Ther 20, no. 5 (2015): 457–67. https://doi.org/10.3851/IMP2910.Full Text Link to Item
-
Sulkowski, Mark S., Susanna Naggie, Jacob Lalezari, Walford Jeffrey Fessel, Karam Mounzer, Margaret Shuhart, Anne F. Luetkemeyer, et al. “Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.” Jama 312, no. 4 (July 23, 2014): 353–61. https://doi.org/10.1001/jama.2014.7734.Full Text Link to Item
-
Molina, J. M., S. Naggie, M. Sulkowski, J. Lalezari, J. Mchutchison, D. Dieterich, and M. Rodriguez-Torres. “[In Process Citation].” Med Mal Infect 44, no. 6 Suppl (June 2014): 1–2. https://doi.org/10.1016/S0399-077X(14)70041-1.Full Text Link to Item
-
Norton, B. L., C. I. Voils, S. H. Timberlake, E. J. Hecker, N. D. Goswami, K. M. Huffman, A. Landgraf, S. Naggie, and J. E. Stout. “Community-based HCV screening: Knowledge and attitudes in a high risk urban population.” Bmc Infectious Diseases 14, no. 1 (March 10, 2014). https://doi.org/10.1186/1471-2334-14-74.Full Text
-
Norton, Brianna L., Corrine I. Voils, Sarah H. Timberlake, Emily J. Hecker, Neela D. Goswami, Kim M. Huffman, Anneka Landgraf, Susanna Naggie, and Jason E. Stout. “Community-based HCV screening: knowledge and attitudes in a high risk urban population.” Bmc Infectious Diseases 14 (February 10, 2014): 74. https://doi.org/10.1186/1471-2334-14-74.Full Text Open Access Copy
-
Goswami, Neela D., Ephraim L. Tsalik, Susanna Naggie, William C. Miller, John R. Horton, Christopher D. Pfeiffer, and Charles B. Hicks. “A cross-sectional analysis of HIV and hepatitis C clinical trials 2007 to 2010: the relationship between industry sponsorship and randomized study design.” Trials 15 (January 22, 2014): 31. https://doi.org/10.1186/1745-6215-15-31.Full Text
-
Bruno, Theodore O., Charles B. Hicks, Susanna Naggie, David A. Wohl, Helmut Albrecht, Nathan M. Thielman, Daniel U. Rabin, et al. “VISION: a regional performance improvement initiative for HIV health care providers.” The Journal of Continuing Education in the Health Professions 34, no. 3 (January 2014): 171–78. https://doi.org/10.1002/chp.21248.Full Text
-
Chastain, Cody A., and Susanna Naggie. “Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014.” Current Hiv/Aids Reports 10, no. 4 (December 2013): 408–19. https://doi.org/10.1007/s11904-013-0182-8.Full Text
-
Osinusi, Anuoluwapo, and Susanna Naggie. “Boceprevir for HCV in patients with HIV: where next?” The Lancet. Infectious Diseases 13, no. 7 (July 2013): 563–64. https://doi.org/10.1016/s1473-3099(13)70162-2.Full Text
-
Naggie, Susanna. “Management of hepatitis C virus infection: the basics.” Top Antivir Med 20, no. 5 (December 2012): 154–61.Link to Item
-
Osinusi, Anu, Aarthi Chary, Mark A. Winters, Susanna Naggie, Henry Masur, Michael A. Polis, Shyam Kottilil, and Mark Holodniy. “IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin.” J Med Virol 84, no. 10 (October 2012): 1522–27. https://doi.org/10.1002/jmv.23376.Full Text Link to Item
-
Clark, P. J., A. J. Thompson, Q. Zhu, D. M. Vock, M. Zhu, K. Patel, S. A. Harrison, et al. “Erratum: The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis c infection (Digestive Diseases and Sciences (2012) 57 (2479)).” Digestive Diseases and Sciences 57, no. 9 (September 1, 2012): 2479. https://doi.org/10.1007/s10620-012-2309-y.Full Text
-
Norton, Brianna L., Lawrence Park, Leah J. McGrath, Rae Jean Proeschold Bell, Andrew J. Muir, and Susanna Naggie. “Health care utilization in HIV-infected patients: assessing the burden of hepatitis C virus coinfection.” Aids Patient Care Stds 26, no. 9 (September 2012): 541–45. https://doi.org/10.1089/apc.2012.0170.Full Text Link to Item
-
Clark, Paul J., Alexander J. Thompson, Qianqian Zhu, David M. Vock, Mingfu Zhu, Keyur Patel, Stephen A. Harrison, et al. “The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection.” Dig Dis Sci 57, no. 8 (August 2012): 2213–21. https://doi.org/10.1007/s10620-012-2171-y.Full Text Link to Item
-
Naggie, Susanna, Anu Osinusi, Antonios Katsounas, Richard Lempicki, Eva Herrmann, Alexander J. Thompson, Paul J. Clark, et al. “Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response.” Hepatology 56, no. 2 (August 2012): 444–54. https://doi.org/10.1002/hep.25647.Full Text Link to Item
-
Osinusi, Anu, Susanna Naggie, Seerat Poonia, Martin Trippler, Zonghui Hu, Emily Funk, Joerg Schlaak, et al. “ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV.” J Med Virol 84, no. 7 (July 2012): 1106–14. https://doi.org/10.1002/jmv.23302.Full Text Link to Item
-
Clark, P. J., A. J. Thompson, M. Zhu, D. M. Vock, Q. Zhu, D. Ge, K. Patel, et al. “Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response.” J Viral Hepat 19, no. 5 (May 2012): 332–40. https://doi.org/10.1111/j.1365-2893.2011.01553.x.Full Text Link to Item
-
Naggie, Susanna, and Mark S. Sulkowski. “Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.” Gastroenterology 142, no. 6 (May 2012): 1324-1334.e3. https://doi.org/10.1053/j.gastro.2012.02.012.Full Text
-
Rallón, Norma I., Vincent Soriano, Susanna Naggie, Clara Restrepo, John McHutchison, Eugenia Vispo, and José M. Benito. “Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV.” The Journal of Antimicrobial Chemotherapy 67, no. 5 (May 2012): 1246–49. https://doi.org/10.1093/jac/dkr598.Full Text
-
Jazwinski, A. B., A. J. Thompson, P. J. Clark, S. Naggie, H. L. Tillmann, and K. Patel. “Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis.” J Viral Hepat 19, no. 4 (April 2012): 278–82. https://doi.org/10.1111/j.1365-2893.2011.01546.x.Full Text Link to Item
-
Proeschold-Bell, Rae Jean, Ashwin A. Patkar, Susanna Naggie, Lesleyjill Coward, Paolo Mannelli, Jia Yao, Patricia Bixby, and Andrew J. Muir. “An integrated alcohol abuse and medical treatment model for patients with hepatitis C.” Dig Dis Sci 57, no. 4 (April 2012): 1083–91. https://doi.org/10.1007/s10620-011-1976-4.Full Text Open Access Copy Link to Item
-
Naggie, Susanna, Norma I. Rallon, José M. Benito, Judith Morello, Sonia Rodriguez-Novoa, Paul J. Clark, Alexander J. Thompson, et al. “Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes.” J Infect Dis 205, no. 3 (February 1, 2012): 376–83. https://doi.org/10.1093/infdis/jir754.Full Text Link to Item
-
Thompson, Alexander J., Paul J. Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mingfu Zhu, Qianqian Zhu, et al. “Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.” J Hepatol 56, no. 2 (February 2012): 313–19. https://doi.org/10.1016/j.jhep.2011.04.021.Full Text Link to Item
-
Goswami, Neela D., Emily J. Hecker, Carter Vickery, Marshall A. Ahearn, Gary M. Cox, David P. Holland, Susanna Naggie, et al. “Geographic information system-based screening for TB, HIV, and syphilis (GIS-THIS): a cross-sectional study.” Plos One 7, no. 10 (2012): e46029. https://doi.org/10.1371/journal.pone.0046029.Full Text Open Access Copy Link to Item
-
Osinusi, A., and S. Naggie. “The role of IL28B genotype testing in the era of direct acting antiviral agents.” European Gastroenterology and Hepatology Review 8, no. 1 (January 1, 2012): 33–39.
-
Osinusi, Anu, and Susanna Naggie. “The Role of IL28B Genotype Testing in the Era of Direct Acting Antiviral Agents.” Eur Gastroenterol Hepatol Rev 1, no. 2 (2012): 33–39.Link to Item
-
Goswami, Neela D., Emily Hecker, David P. Holland, Susanna Naggie, Gary M. Cox, Ann Mosher, Debbie Turner, et al. “Feasibility and willingness-to-pay for integrated community-based tuberculosis testing.” Bmc Infectious Diseases 11 (November 2, 2011): 305. https://doi.org/10.1186/1471-2334-11-305.Full Text Open Access Copy
-
Sidique, Nadeera, Anita Kohli, Bhavana Shivakumar, Stephen Migueles, G Mani Subramanian, Susanna Naggie, Michael A. Polis, Henry Masur, and Shyam Kottilil. “HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients.” J Acquir Immune Defic Syndr 58, no. 2 (October 1, 2011): e38–40. https://doi.org/10.1097/QAI.0b013e31822d463f.Full Text Link to Item
-
Barreiro, Pablo, Juan Antonio Pineda, Norma Rallón, Susanna Naggie, Luz Martín-Carbonero, Karin Neukam, Antonio Rivero, et al. “Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy.” J Infect Dis 203, no. 11 (June 1, 2011): 1629–36. https://doi.org/10.1093/infdis/jir113.Full Text Link to Item
-
Rallón, Norma I., Vincent Soriano, Susanna Naggie, Clara Restrepo, David Goldstein, Eugenia Vispo, John McHutchison, and José M. Benito. “IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.” Aids 25, no. 8 (May 15, 2011): 1025–33. https://doi.org/10.1097/QAD.0b013e3283471cae.Full Text Link to Item
-
Jazwinski, Alison, Susanna Naggie, and John Perfect. “Immune reconstitution syndrome in a patient with disseminated histoplasmosis and steroid taper: maintaining the perfect balance.” Mycoses 54, no. 3 (May 2011): 270–72. https://doi.org/10.1111/j.1439-0507.2009.01796.x.Full Text Link to Item
-
Naggie, S. N. “Investigational Agents for Chronic Viral Infections: HIV and HCV.” Journal of Neuroimmune Pharmacology 6 (April 1, 2011): S18–S18.Link to Item
-
Naggie, Susanna, Becky A. Miller, Kimberly B. Zuzak, Brian W. Pence, Ashley J. Mayo, Bradly P. Nicholson, Preeta K. Kutty, L Clifford McDonald, and Christopher W. Woods. “A case-control study of community-associated Clostridium difficile infection: no role for proton pump inhibitors.” Am J Med 124, no. 3 (March 2011): 276.e1-276.e7. https://doi.org/10.1016/j.amjmed.2010.10.013.Full Text Link to Item
-
Rallon, Norma I., Clara Restrepo, Susanna Naggie, Mariola Lopez, Jorge Del Romero, David Goldstein, John McHutchison, Vincent Soriano, and Jose M. Benito. “Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline.” Aids 25, no. 2 (January 14, 2011): 269–71. https://doi.org/10.1097/QAD.0b013e328341b84e.Full Text Link to Item
-
Thompson, Alexander J., Andrew J. Muir, Mark S. Sulkowski, Keyur Patel, Hans L. Tillmann, Paul J. Clark, Susanna Naggie, et al. “Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.” Hepatology 52, no. 6 (December 2010): 2243–44. https://doi.org/10.1002/hep.23826.Full Text Link to Item
-
Medrano, Jose, Karin Neukam, Norma Rallón, Antonio Rivero, Salvador Resino, Susanna Naggie, Antonio Caruz, et al. “Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.” Clin Infect Dis 51, no. 10 (November 15, 2010): 1209–16. https://doi.org/10.1086/656811.Full Text Link to Item
-
Thompson, A. J., R. Santoro, V. Piazzolla, P. J. Clark, S. Naggie, H. L. Tillmann, K. Patel, et al. “Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.” Hepatology, November 12, 2010. https://doi.org/10.1002/hep.24068.Full Text Link to Item
-
Naggie, Susanna, Keyur Patel, and John McHutchison. “Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.” J Antimicrob Chemother 65, no. 10 (October 2010): 2063–69. https://doi.org/10.1093/jac/dkq284.Full Text Link to Item
-
Thompson, Alexander J., Jacques Fellay, Keyur Patel, Hans L. Tillmann, Susanna Naggie, Dongliang Ge, Thomas J. Urban, et al. “Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.” Gastroenterology 139, no. 4 (October 2010): 1181–89. https://doi.org/10.1053/j.gastro.2010.06.016.Full Text Link to Item
-
Person, Anna K., Neela D. Goswami, Deborah J. Bissette, Debra S. Turner, Ann V. Baker, L Beth Gadkowski, Susanna Naggie, et al. “Pairing QuantiFERON gold in-tube with opt-out HIV testing in a tuberculosis contact investigation in the Southeastern United States.” Aids Patient Care Stds 24, no. 9 (September 2010): 539–43. https://doi.org/10.1089/apc.2010.0102.Full Text Open Access Copy Link to Item
-
Naggie, S., J. Frederick, B. C. Pien, B. A. Miller, D. T. Provenzale, K. C. Goldberg, and C. W. Woods. “Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA.” Infection 38, no. 4 (August 2010): 297–300. https://doi.org/10.1007/s15010-010-0025-0.Full Text Link to Item
-
Naggie, Susanna, and Charles Hicks. “Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients: the evidence behind the options.” J Antimicrob Chemother 65, no. 6 (June 2010): 1094–99. https://doi.org/10.1093/jac/dkq130.Full Text Link to Item
-
Rallón, Norma I., Susanna Naggie, José M. Benito, José Medrano, Clara Restrepo, David Goldstein, Kevin V. Shianna, et al. “Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.” Aids 24, no. 8 (May 15, 2010): F23–29. https://doi.org/10.1097/QAD.0b013e3283391d6d.Full Text Link to Item
-
Kutty, Preeta K., Christopher W. Woods, Arlene C. Sena, Stephen R. Benoit, Susanna Naggie, Joyce Frederick, Sharon Evans, Jeffery Engel, and L Clifford McDonald. “Risk factors for and estimated incidence of community-associated Clostridium difficile infection, North Carolina, USA.” Emerg Infect Dis 16, no. 2 (February 2010): 197–204. https://doi.org/10.3201/eid1602.090953.Full Text Open Access Copy Link to Item
-
Naggie, Susanna, Tsung Hseih, Jennifer Reckleff, Joe Castellano, and Charles B. Hicks. “Treatment and CD4+ T cell count recovery among antiretroviral therapy-naive patients with HIV/AIDS.” Clin Infect Dis 49, no. 10 (November 15, 2009): 1619–20. https://doi.org/10.1086/644776.Full Text Link to Item
-
Naggie, Susanna, and John R. Perfect. “Molds: hyalohyphomycosis, phaeohyphomycosis, and zygomycosis.” Clin Chest Med 30, no. 2 (June 2009): 337–viii. https://doi.org/10.1016/j.ccm.2009.02.009.Full Text Link to Item
-
Kutty, Preeta K., Stephen R. Benoit, Christopher W. Woods, Arlene C. Sena, Susanna Naggie, Joyce Frederick, John Engemann, et al. “Assessment of Clostridium difficile-associated disease surveillance definitions, North Carolina, 2005.” Infect Control Hosp Epidemiol 29, no. 3 (March 2008): 197–202. https://doi.org/10.1086/528813.Full Text Link to Item
-
Morpeth, Susan C., John A. Crump, Humphrey J. Shao, Habib O. Ramadhani, Peter R. Kisenge, Cindy A. Moylan, Susanna Naggie, et al. “Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population.” Aids Res Hum Retroviruses 23, no. 10 (October 2007): 1230–36. https://doi.org/10.1089/aid.2007.0053.Full Text Link to Item
-
Pham, M. Q., S. Naggie, M. Wier, H. J. Cha, and W. E. Bentley. “Human interleukin-2 production in insect (Trichoplusia ni) larvae: effects and partial control of proteolysis.” Biotechnol Bioeng 62, no. 2 (January 20, 1999): 175–82. https://doi.org/10.1002/(sici)1097-0290(19990120)62:2<175::aid-bit7>3.0.co;2-j.Full Text Link to Item
-
Naggie, S., and W. E. Bentley. “Appearance of protease activities coincides with p10 and polyhedrin-driven protein production in the baculovirus expression system: effects on yield.” Biotechnol Prog 14, no. 2 (March 1998): 227–32. https://doi.org/10.1021/bp980002b.Full Text Link to Item
-
Naggie, S., Y. C. Hu, T. R. Pulliam-Holoman, and W. E. Bentley. “Substrate (gelatin) gel electrophoretic method for analysis of protease activity in insect (Sf-9) cells.” Biotechnology Techniques 11, no. 5 (January 1, 1997): 297–300. https://doi.org/10.1023/A:1018411210412.Full Text
-
Naggie, Susanna. “Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time.” Top Antivir Med 25, no. 1 (n.d.): 3–6.Link to Item
-
-
Conference Papers
-
Schwartz, Zachary, Jenny Schulz, Edward King, Susanna Naggie, and Mark S. Sulkowski. “VARIANCE BETWEEN CLINICIANS AND GUIDELINES IN MANAGEMENT OF HIV/HCV COINFECTION.” In Hepatology, 70:952A-952A. WILEY, 2019.Link to Item
-
Gutierrez, Julio, Eli Zuckerman, Andrew Ustianowski, Susanna Naggie, Florin Caruntu, Natarajan Ravendhran, Samuel Sigal, et al. “EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS: ANALYSIS OF DATA POOLED FROM PHASE 2 AND 3 STUDIES.” In Gastroenterology, 156:S1218–S1218. W B SAUNDERS CO-ELSEVIER INC, 2019.Link to Item
-
Lee, Tzu-Hao, Austin Chan, William E. Bryan, Lawrence Park, Mohamed Hashem, Mary Townsend, Cynthia A. Moylan, Rachel B. Britt, Steve S. Choi, and Susanna Naggie. “USAGE OF PPI REDUCES THE SVR RATE FOR HIV-HCV COINFECTED PATIENTS USING LEDIPASVIR/SOFOSBUVIR: A REAL-WORLD STUDY FROM MULTICENTER VA COHORT.” In Gastroenterology, 156:S1345–S1345. W B SAUNDERS CO-ELSEVIER INC, 2019.Link to Item
-
Zuckerman, Eli, Julio Gutierrez, Andrew Ustianowski, Susanna Naggie, Florin Alexandru Caruntu, Natarajan Ravendhran, Samuel Sigal, et al. “Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies.” In Journal of Hepatology, 70:E251–E251. ELSEVIER, 2019.Link to Item
-
Clement, Meredith, Mira Nicchitta, Alicia Ellis, Sarah Hale, Hrishikesh Chakraborty, Kara McGee, Cedar Eagle, et al. “Outcomes for PrEP Users in the Southern US: Persistence and STIs.” In Aids Research and Human Retroviruses, 34:258–258. MARY ANN LIEBERT, INC, 2018.Link to Item
-
Muir, Andrew Joseph, Jia Yao, Julius Wilder, Christina Makarushka, Kelly Keefe, James Henry Helzberg, Paolo Mannelli, et al. “The Alcohol Use Disorders Identification Test Screening in Patients with Hepatitis C.” In Hepatology, 68:908A-908A. WILEY, 2018.Link to Item
-
Wilder, Julius M., Jia Yao, Makarushka Christina, Donna Evon, Michael W. Fried, Susanna Naggie, Andrew J. Muir, and Rae Jean Proeschold-Bell. “ASSOCIATIONS OF ALCOHOL CONSUMPTION MOTIVES WITH DEPRESSION AND PAIN AMONG INDIVIDUALS WITH HEPATITIS C.” In Gastroenterology, 154:S1121–22. W B SAUNDERS CO-ELSEVIER INC, 2018.Link to Item
-
Naggie, Susanna, Daniel S. Fierer, Michael Hughes, Arthur Y. Kim, Anne Luetkemeyer, Vincent Vu, Jhoanna Roa, et al. “100% SVR with 8 weeks of ledipasvir/sofosbuvir in HIV-infected Men with Acute HCV Infection: Results from the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals).” In Hepatology, 66:113A-113A. WILEY, 2017.Link to Item
-
Naggie, Susanna, Kristen M. Marks, Michael Hughes, Daniel S. Fierer, Christine Macbrayne, Arthur Kim, Kimberly Hollabaugh, et al. “Sofosbuvir Plus Ribavirin Without Interferon for Treatment of Acute Hepatitis C Virus Infection in HIV-1-Infected Individuals: SWIFT-C.” In Clin Infect Dis, 64:1035–42, 2017. https://doi.org/10.1093/cid/cix025.Full Text Link to Item
-
Younossi, Z. M., M. Stepanova, M. Sulkowski, S. Naggie, L. Henry, and S. Hunt. “Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.” In J Viral Hepat, 23:857–65, 2016. https://doi.org/10.1111/jvh.12554.Full Text Link to Item
-
Asselah, Tarik, Gamal Shiha, Jordan J. Feld, Armando Abergel, Anita Kohli, Shyam Kottilil, Peter J. Ruane, et al. “Integrated Analysis of SOF plus RBV, LDV/SOF or SOF/VEL for the Treatment of Genotype 4 Chronic HCV Infection.” In Hepatology, 64:40A-41A. WILEY, 2016.Link to Item
-
Chan, Austin W., William E. Bryan, Mohamed A. Hashem, Mary L. Townsend, Laura Ann Wang, Steve S. Choi, and Susanna Naggie. “Hepatitis C (HCV) Virologic Outcomes in Veterans taking Ledipasvir/Sofosbuvir with Concomitant Acid Suppressing Medication.” In Hepatology, 64:468A-468A. WILEY, 2016.Link to Item
-
Fuchs, Michael, Timothy R. Morgan, Mariem Charafeddine, Norbert Brau, Warren N. Schmidt, Michael Kozal, Susanna Naggie, et al. “An Open-Label, Multicenter Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin in US Veterans with Genotype 1 Chronic Hepatitis C Infection: Efficacy and Safety Results of TOPAZ-VA.” In Hepatology, 64:488A-488A. WILEY, 2016.Link to Item
-
Naggie, Susanna, Eric Rosenthal, Sarah Kattakuzhy, Justin McGinnis, Sarjita Naik, Macky Natha, Joseph Llewellyn, et al. “Real World Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) in Patients Coinfected With HCV and HIV-1: A Comparative Analysis of Clinical Trials with Four Real World Cohorts.” In Hepatology, 64:445A-445A. WILEY, 2016.Link to Item
-
Sulkowski, Mark S., Curtis Cooper, Jean-Michel Molina, Susanna Naggie, K. C. Huang, Anu O. Osinusi, Luisa M. Stamm, et al. “High Rates of Medical and Psychiatric Comorbidities in HIV/HCV Coinfected Patients Treated With Sofosbuvir-Containing Regimens in Registrational Clinical Trials.” In Hepatology, 64:482A-483A. WILEY, 2016.Link to Item
-
Wyles, David, Norbert Brau, Susanna Naggie, Mark Sulkowski, Kosh Agarwal, Keyur Patel, Nezam Afdhal, et al. “SOF/VEL single-tablet regimen in HCV mono-infected and HIV/HCV co-infected patients: comparison of efficacy and safety data from phase 3 clinical trials.” In Journal of the International Aids Society, Vol. 19. JOHN WILEY & SONS LTD, 2016.Link to Item
-
Braeu, N., D. Wyles, S. Kottilil, E. Darr, K. Workowski, A. Luetkemeyer, O. Adeyemi, et al. “Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1: the phase.” In Journal of the International Aids Society, Vol. 19. JOHN WILEY & SONS LTD, 2016.Link to Item
-
Patel, Keyur, Georgina Kilfoil, David L. Wyles, Susanna Naggie, Eric Lawitz, Stephen Bradley, Per Lindell, and David Suhy. “258. Phase I/IIa Study of TT-034, a DNA-Directed RNA Interference (ddRNAi) Agent Delivered as a Single Administration for the Treatment of Subjects with Chronic Hepatitis C Virus (HCV).” In Molecular Therapy, 24:S102–S102. Elsevier BV, 2016. https://doi.org/10.1016/s1525-0016(16)33067-2.Full Text
-
Alam, Imtiaz, Kimberley Brown, Cynthia Donovan, Jamie Forlenza, Kris Lauwers, Mitchell A. Mah’moud, Richard A. Manch, et al. “Su1426 Effectiveness of Simeprevir-Containing Regimens Among Patients With Chronic Hepatitis C Virus in Various US Practice Settings: The SONET Study.” In Gastroenterology, 150:S1096–97. Elsevier BV, 2016. https://doi.org/10.1016/s0016-5085(16)33703-9.Full Text
-
Ruane, Peter J., Gamal Shiha, Armand Abergel, Tarik Asselah, Anita Kohli, Shyam Kottilil, Susanna Naggie, et al. “756 Integrated Analysis of Sof+RBV or LDV/Sof for the Treatment of Genotype 4 Chronic HCV Infection.” In Gastroenterology, 150:S1047–48. Elsevier BV, 2016. https://doi.org/10.1016/s0016-5085(16)33541-7.Full Text
-
Alam, I., K. Brown, C. Donovan, J. Forlenza, K. Lauwers, M. A. Mah’moud, R. Manch, et al. “Effectiveness of Simeprevir-Containing Regimens among Patients with Chronic Hepatitis C Virus in Various Us Practice Settings: The Sonet Study.” In Journal of Hepatology, 64:S773–S773. Elsevier BV, 2016. https://doi.org/10.1016/s0168-8278(16)01507-5.Full Text
-
Esmat, G. E., G. Shiha, A. Abergel, T. Asselah, A. Kohli, S. Kottilil, P. J. Ruane, et al. “INTEGRATED ANALYSIS OF SOF plus RBV OR LDV/SOF FOR THE TREATMENT OF GENOTYPE 4 CHRONIC HCV INFECTION.” In Journal of Hepatology, 64:S769–S769. ELSEVIER SCIENCE BV, 2016.Link to Item
-
Wyles, D., N. Brau, S. Kottilil, E. Daar, K. Workowski, A. Luetkemeyer, O. Adeyemi, et al. “Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Patients Co-Infected with HCV and HIV-1: The Phase 3 Astral-5 Study.” In Journal of Hepatology, 64:S188–89. Elsevier BV, 2016. https://doi.org/10.1016/s0168-8278(16)00129-x.Full Text
-
Rabatin, Abigail, Mohamed Hashem, Mary L. Townsend, William E. Bryan, Cynthia A. Moylan, Steve S. Choi, and Susanna Naggie. “Treatment Outcomes of Veterans with Decompensated Cirrhosis Receiving All Oral Direct Acting Antiviral Hepatitis C Therapy.” In Hepatology, 62:773A-773A. WILEY-BLACKWELL, 2015.Link to Item
-
Alam, I., R. Manch, S. Naggie, R. Reindollar, J. Slim, A. Prabhakar, K. Lauwers, et al. “P0826 : Effectiveness of simeprevir (SMV)-containing regimens among patients with chronic hepatitis C virus (HCV) in various us practice settings: Interim analysis of the sonet study.” In Journal of Hepatology, 62:S646–47. Elsevier BV, 2015. https://doi.org/10.1016/s0168-8278(15)31029-1.Full Text
-
Cooper, C., S. Naggie, M. Saag, J. Yang, L. Stamm, P. Pang, J. McHutchison, D. Dieterich, and M. Sulkowski. “P1353 : A single tablet regimen of ledipasvir/sofosbuvir for 12 weeks in HCV genotype 1 or 4 infected patients with HIV-1 co-infection : The phase 3 ION-4 study.” In Journal of Hepatology, 62:S675–76. Elsevier BV, 2015. https://doi.org/10.1016/s0168-8278(15)31090-4.Full Text
-
Naggie, Susanna, Imtaiz Alam, Richard A. Manch, Robert Reindollar, Jihad Slim, Avi Prabhakar, Kris Lauwers, et al. “Effectiveness of Simeprevir (SMV) - Containing Regimens Among Patients With Chronic Hepatitis C Virus (HCV) in Various US Practice Settings: Interim Analysis of the Sonet Study.” In Gastroenterology, 148:S1090–S1090. W B SAUNDERS CO-ELSEVIER INC, 2015.Link to Item
-
Swiderska-Syn, M., S. Choi, A. Lan, G. Ferrari, A. M. Diehl, and S. Naggie. “P0469 : Markers of tissue repair and cellular aging are increased in liver tissue of patients with dual chronic HIV/HCV infections.” In Journal of Hepatology, 62:S489–S489. Elsevier BV, 2015. https://doi.org/10.1016/s0168-8278(15)30677-2.Full Text
-
Naggie, S., M. Sulkowski, A. Gaggar, L. Stamm, L. Ni, D. Brainard, W. Symonds, J. McHutchison, D. Dieterich, and M. Rodriguez-Torres. “P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS.” In Journal of Hepatology, 60:S475–76. Elsevier BV, 2014. https://doi.org/10.1016/s0168-8278(14)61333-7.Full Text
-
Rockstroh, Juergen K., Massimo Puoti, Maribel Rodriguez-Torres, Douglas Dieterich, Anuj Gaggar, Liyun Ni, Benedetta Massetto, et al. “Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials.” In Hepatology, 60:295A-296A. WILEY-BLACKWELL, 2014.Link to Item
-
Younossi, Zobair, Maria Stepanova, Mark S. Sulkowski, Susanna Naggie, and Sharon L. Hunt. “Patient-Reported Outcomes (PROs) in HIV-HCV Co-infected Patients Treated with Sofosbuvir (SOF)-containing Regimens.” In Hepatology, 60:891A-891A. WILEY-BLACKWELL, 2014.Link to Item
-
Sulkowski, Mark S., Maribel Rodriguez-Torres, Jacob P. Lalezari, W Jeffrey Fessel, Karam Mounzer, Margaret C. Shuhart, Anne Luetkemeyer, et al. “All-Oral Therapy With Sofosbuvir Plus Ribavirin For the Treatment of HCV Genotype 1, 2, and 3 Infection in Patients Co-infected With HIV (PHOTON-1).” In Hepatology, 58:313A-314A. WILEY-BLACKWELL, 2013.Link to Item
-
Clark, Paul J., Rosanna Santoro, Valeria Piazzolla, Leonardo Mottola, D. Bacca, N. Dello Iacono, Salvatore Grimaldi, et al. “Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major treated for chronic hepatitis C.” In Hepatology, 56:1028A-1029A. WILEY-BLACKWELL, 2012.Link to Item
-
Jones, Lisa, Dawn Piercy, Susanna Naggie, and Manal Abdelmalek. “Drug-Induced Idiopathic Portal Hypertension Mimicking “Cryptogenic” Cirrhosis in a HIV Patient.” In American Journal of Gastroenterology, 107:S426–S426. Ovid Technologies (Wolters Kluwer Health), 2012. https://doi.org/10.14309/00000434-201210001-01053.Full Text
-
Naggie, Susanna, Anu Osinusi, Tiffany Himmel, Joseph Lucas, J. W. Thompson, Laura G. Dubois, Martin A. Moseley, Paul J. Clark, Shyam Kottilil, and Keyur Patel. “Targeted proteomics signature identifies corticosteroid binding globulin peptides as highly predictive of treatment response in IL28B unfavorable genotype patients.” In Hepatology, 56:999A-1000A. WILEY-BLACKWELL, 2012.Link to Item
-
Clark, Paul J., Alexander J. Thompson, Alison Jazwinski, Hans L. Tillmann, Susanna Naggie, Andrew J. Muir, and Keyur Patel. “Association of Serum Adipocytokines With IL28B and SVR in Chronic Hepatitis C.” In Gastroenterology, 142:S968–69. W B SAUNDERS CO-ELSEVIER INC, 2012.Link to Item
-
Clark, P. J., A. J. Thompson, H. L. Tillmann, A. Jazwinski, S. Naggie, A. J. Muir, and K. Patel. “884 EXPLORATION OF SERUM ADIPOCYTOKINE ASSOCIATIONS WITH IL28B GENOTYPE IN CHRONIC HEPATITIS C.” In Journal of Hepatology, 56:S344–S344. Elsevier BV, 2012. https://doi.org/10.1016/s0168-8278(12)60896-4.Full Text
-
Clark, Paul J., Alexander J. Thompson, Thomas J. Urban, Keyur Patel, David M. Vock, Qianqian Zhu, Alison Jazwinski, et al. “PNPLA3 GENOTYPE RATHER THAN RACE MAY EXPLAIN THE LOWER PREVALENCE OF HEPATIC STEATOSIS DESPITE WORSE METABOLIC RISK FACTORS IN AFRICAN AMERICAN PATIENTS WITH CHRONIC HEPATITIS C (CHC).” In Hepatology, 54:402A-402A. WILEY-BLACKWELL, 2011.Link to Item
-
Gellad, Ziad F., Susanna Naggie, Shelby D. Reed, Paul J. Clark, Alex J. Thompson, Kevin A. Schulman, and Andrew J. Muir. “THE COST-EFFECTIVENESS OF A TELAPREVIR-INCLUSIVE REGIMEN AS INITIAL THERAPY FOR GENOTYPE 1 HEPATITIS C INFECTION IN INDIVIDUALS WITH THE CC IL-28B POLYMORPHISM.” In Hepatology, 54:417A-418A. WILEY-BLACKWELL, 2011.Link to Item
-
Kohli, Anita, Susanna Naggie, Michael A. Polis, Henry Masur, and Shyam Kottilil. “HIV/HCV-COINFECTED NATURAL VIRAL SUPPRESSORS HAVE BETTER VIROLOGIC RESPONSES TO PEG-IFN AND RIBAVIRIN THAN ARV-TREATED HIV/HCV PATIENTS.” In Hepatology, 54:847A-847A. WILEY-BLACKWELL, 2011.Link to Item
-
Osinusi, Anu, Aarthi Chary, Shyam Kottilil, Mark A. Winters, Susanna Naggie, Henry Masur, Michael A. Polis, and Mark Holodniy. “IL28B POLYMORPHISM IS NOT ASSOCIATED WITH HCV PROTEASE DIVERSITY IN HIV/HCV-COINFECTED PATIENTS TREATED WITH AN INTERFERON-BASED REGIMEN.” In Hepatology, 54:815A-815A. WILEY-BLACKWELL, 2011.Link to Item
-
Osinusi, Anu, Susanna Naggie, Seerat Poonia, Martin Trippler, Zonghui Hu, Emily Funk, Joerg F. Schlaak, et al. “ITPA GENE POLYMORPHISMS SIGNIFICANTLY AFFECT HEMOGLOBIN DECLINE AND TREATMENT OUTCOMES IN HIV/HCV CO-INFECTED PATIENTS.” In Hepatology, 54:854A-854A. WILEY-BLACKWELL, 2011.Link to Item
-
Thompson, Alexander J., Paul J. Clark, David M. Vock, Ruth Pfeiffer, Hans L. Tillmann, Keyur Patel, Susanna Naggie, et al. “PREDICTING PEGINTERFERON-alpha AND RIBAVIRIN TREATMENT RESPONSE IN GENOTYPE 1 HCV PATIENTS - SIMPLE NOMOGRAMS TO SUPPORT CLINICIANS.” In Hepatology, 54:803A-804A. WILEY-BLACKWELL, 2011.Link to Item
-
Thompson, Alexander J., Paul J. Clark, Hans L. Tillmann, Keyur Patel, Susanna Naggie, F Fred Poordad, Eric Lawitz, et al. “IL28B C/C GENOTYPE IS PREDICTIVE OF >= 1 LOG10 IU/ML REDUCTION IN PLASMA HCV RNA AFTER 4 WEEKS OF PEGINTERFERON (PEGIFN) AND RIBAVIRIN (RBV) THERAPY: IMPLICATIONS FOR THE USE OF THE LEAD-IN STRATEGY FOR DIRECT-ACTING ANTIVIRAL-BASED TREATMENT REGIMENS.” In Hepatology, 54:436A-437A. WILEY-BLACKWELL, 2011.Link to Item
-
Naggie, S., A. Osinusi, A. Katsounas, R. Lempicki, E. Herrmann, B. Shivakumar, A. Thompson, et al. “1334 DYSREGULATION OF HOST INNATE IMMUNITY IN HCV GENOTYPE 1 INFECTED IL28B CT/TT HAPLOTYPE PATIENTS WITH DEPRESSED VIRAL KINETICS AND THERAPEUTIC RESPONSE.” In Journal of Hepatology, 54:S526–27. Elsevier BV, 2011. https://doi.org/10.1016/s0168-8278(11)61336-6.Full Text
-
Rallon, N. I., S. Naggie, C. Restrepo, J. McHutchison, V. Soriano, and J. M. Benito. “IL28B genotypes strongly influence early viral kinetics in HIV/HCV-coinfected patients treated with peginterferon-alpha/ribavirin - implications using directly acting antivirals.” In Antiviral Therapy, 16:A91–A91. INT MEDICAL PRESS LTD, 2011.Link to Item
-
Clark, Paul J., Alexander J. Thompson, Mingfu Zhu, Qianqian Zhu, Dongliang Ge, Mark S. Sulkowski, Hans L. Tillmann, et al. “IL28B GENETIC POLYMORPHISM HAS GENOME WIDE SIGNIFICANT ASSOCIATIONS WITH SERUM LOW DENSITY LIPOPROTEIN LEVELS AND HEPATIC STEATOSIS IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (CHC).” In Hepatology, 52:439A-440A. WILEY, 2010.Link to Item
-
Naggie, Susanna, Norma I. Rallon, Jose M. Benito, Judith Morello, Sonia Rodriguez-Novoa, Paul J. Clark, Alexander J. Thompson, et al. “VARIANTS IN THE ITPA GENE PROTECT AGAINST EARLY RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA IN HIV/HCV CO-INFECTED PATIENTS.” In Hepatology, 52:776A-776A. WILEY-BLACKWELL, 2010.Link to Item
-
Rallon, Norma I., Susanna Naggie, Clara Restrepo, David B. Goldstein, John G. McHutchison, Vincent Soriano, and Jose M. Benito. “THE IL28B CC GENOTYPE STRONGLY PREDICTS EARLY VIRAL KINETICS IN HIV-INFECTED PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON-RIBAVIRIN.” In Hepatology, 52:385A-385A. WILEY-BLACKWELL, 2010.Link to Item
-
Rollon, Norma I., Susanna Naggie, Clara Restrepo, David B. Goldstein, John G. McHutchison, Vincent Soriano, and Jose M. Benito. “IL28B PLASMA LEVELS IN PATIENTS WITH DISTINCT IL28B SNP POLYMORPHISMS AND ASSOCIATION WITH TREATMENT OUTCOME.” In Hepatology, 52:732A-732A. WILEY-BLACKWELL, 2010.Link to Item
-
Thompson, Alexander J., Abanish Singh, Jacques Fellay, Dongliang Ge, Mark S. Sulkowski, Andrew J. Muir, Hans L. Tillmann, et al. “GENOME-WIDE ASSOCIATION STUDY IDENTIFIES AN ASSOCIATION BETWEEN ITPA GENE VARIANTS AND IFN-INDUCED THROMBOCYTOPENIA IN CHRONIC HEPATITIS C PATIENTS FROM THE IDEAL STUDY.” In Hepatology, 52:362A-363A. WILEY, 2010.Link to Item
-
Thompson, Alexander J., Andrew J. Muir, Mark S. Sulkowski, Keyur Patel, Hans L. Tillmann, Paul J. Clark, Susanna Naggie, et al. “HEPATITIS C TRIALS THAT COMBINE INVESTIGATIONAL AGENTS WITH PEGYLATED-INTERFERON-alpha SHOULD BE STRATIFIED BY IL28B GENOTYPE.” In Hepatology, 52:708A-709A. WILEY-BLACKWELL, 2010.Link to Item
-
Thompson, Alexander J., Paul J. Clark, Abanish Singh, Dongliang Ge, Jacques Fellay, Mark S. Sulkowski, Andrew J. Muir, et al. “COMMON GENETIC VARIANTS DO NOT ASSOCIATE WITH IFN-INDUCED NEUTROPENIA IN A GENOME-WIDE ASSOCIATION STUDY OF CHRONIC HEPATITIS C PATIENTS IN THE IDEAL STUDY.” In Hepatology, 52:764A-765A. WILEY, 2010.Link to Item
-
Thompson, Alexander J., Paul J. Clark, Jacques Fellay, Andrew J. Muir, Hans L. Tillmann, Keyur Patel, Susanna Naggie, et al. “IL28B GENOTYPE IS NOT ASSOCIATED WITH ADVANCED HEPATIC FIBROSIS IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY.” In Hepatology, 52:437A-438A. WILEY, 2010.Link to Item
-
Thompson, Alexander J., Paul J. Clark, Mingfu Zhu, Qianqian Zhu, Dongliang Ge, Mark S. Sulkowski, Andrew J. Muir, et al. “GENOME WIDE-ASSOCIATION STUDY IDENTIFIES IL28B POLYMORPHISM TO BE ASSOCIATED WITH BASELINE ALT AND HEPATIC NECRO-INFLAMMATORY ACTIVITY IN CHRONIC HEPATITIS C PATIENTS ENROLLED IN THE IDEAL STUDY.” In Hepatology, 52:1220A-1221A. WILEY, 2010.Link to Item
-
Thompson, Alexander J., Rosanna Santoro, Valeria Piazzolla, Hans L. Tillman, Keyur Patel, Paul J. Clark, Susanna Naggie, et al. “ITPA GENETIC VARIANTS ARE PROTECTIVE AGAINST ANEMIA DURING ANTIVIRAL THERAPY FOR G2/3 HCV, BUT DO NOT DECREASE THE NEED FOR RBV DOSE REDUCTION OR INCREASE SVR.” In Hepatology, 52:785A-786A. WILEY-BLACKWELL, 2010.Link to Item
-
Naggie, S., T. R. Pulliam, and W. E. Bentley. “Elicitation of protease activity in insect (Spodoptera frugiperda) cell cultures.” In Abstracts of Papers of the American Chemical Society, 211:163-BIOT. AMER CHEMICAL SOC, 1996.Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.